Extending the platinum-free interval: The impact of omitting 2nd line platinum chemotherapy in intermediate platinum-sensitive ovarian cancer-Reference-Cited by-同舟云学术

Extending the platinum-free interval: The impact of omitting 2nd line platinum chemotherapy in intermediate platinum-sensitive ovarian cancer

Published:2019-11 Issue:2 Volume:155 Page:201-206
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Dockery Lauren E.,Rubenstein Abby R.,Ding Kai,Mashburn Sarah G.,Burkett Wesley C.,Davis Allison M.,Doo David W.,Arend Rebecca C.,Moore Kathleen N.,Gunderson Camille C.

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,Oncology

Reference17 articles.

1. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse;Pujade-Lauraine;J. Clin. Oncol.,2010

2. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds;Gore;Gynecol. Oncol.,1990

3. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin;Markman;J. Clin. Oncol.,1991

4. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial;Parmar;Lancet,2003

5. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG;Pfisterer;J. Clin. Oncol.,2006

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Poly (ADP-ribose) polymerase inhibitor therapy and mechanisms of resistance in epithelial ovarian cancer;Frontiers in Oncology;2024-07-29

2. MODERN APPROACHES TO THE SYSTEMIC TREATMENT OF RECURRENT OVARIAN CANCER;THE NEW ARMENIAN MEDICAL JOURNAL;2023-04-24

3. A combination of molecular and clinical parameters provides a new strategy for high-grade serous ovarian cancer patient management;Journal of Translational Medicine;2022-12-21

4. Therapy for Recurrent High-Grade Epithelial Ovarian Cancer—The Current Status and Future Trends;Indian Journal of Medical and Paediatric Oncology;2022-09-29

5. Pharmacotherapeutic treatment options for recurrent epithelial ovarian cancer;Expert Opinion on Pharmacotherapy;2022-08-29